Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIN FLOW: Flow-mediated Hyperemia for Slow-flow After PPCI
NCT04685941Completed
- Sponsor
- EPIC Holdings
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
Randomised, open-label trial in coronary microvascular disease (CMD) and myocardial infarction (MI), sponsored by EPIC Holdings. Primary endpoints: Angiographic TIMI frame count at 2 minutes and Minimal microcirculatory resistance at 2 minutes. Started Jan 2021; status: completed.
02
Conditions
coronary microvascular disease (CMD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04685941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04685941.